The Patent Finder

Terms ending in 2032

GlaxoSmithKline LLC

Every in-force patent on GlaxoSmithKline LLC's record whose computed term ends in 2032, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleHolderStatusExpiresConfidence
US 9,271,941Novel Pharmaceutical Composition
In force
 · Low confidence
Novartis Pharmaceuticals CorporationIn forceLow confidence
US 9,868,761Buffer System for Protein Purification
In force
 · High confidence
GlaxoSmithKline Intellectual Property Development LimitedIn forceHigh confidence
US 8,889,726Chemical Compounds
Grace period ended Nov 18, 2026 · lapse expected
 · Low confidence
GlaxoSmithKline LLCGrace period ended Nov 18, 2026
lapse expected
Low confidence
US 9,737,260Methods for Determining Total Body Skeletal Muscle Mass
In force
 · High confidence
The Regents of the University of CaliforniaIn forceHigh confidence
4 of 4 patents shown. Soonest term end first, then patent number.
1 of these is in force and held by GlaxoSmithKline LLC.
Updated Nov 19, 2026 · includes USPTO assignment data published Nov 18, 2026, status data published Nov 19, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 19, 2026 · includes USPTO assignment data published Nov 18, 2026, status data published Nov 19, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited